Mark Sebree serves on the Board of Aktiv, bringing over 35 years of broad experience establishing and implementing strategy in the pharmaceutical industry with focus on early stage and start-up companies. Since 2015, he has served as president and CEO of Incite Pharmaceuticals, a private advisory company. Prior to that, he served as President and CEO of BD Rx as well as in leadership capacities with multiple pharmaceutical companies. Mark has a proven record of leading all functional areas of pharmaceutical operations from early-stage R&D to commercialization. Key accomplishments include the revitalization of and divestiture of a leading generic injectable entity, management of the collaboration that resulted in the first and only $1.0 billion generic injectable drug, and the creation of a new “Ready-to-Administer” prefilled drug/device company. He holds a Master of Business Administration from Lake Forest Graduate School of Management and a Bachelor of Science in Biochemistry and Biophysics from Texas A&M University.

Back to company leadership